GPCR — Structure Therapeutics Inc.
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 163
- Website: https://structuretx.com
Latest SEC filings for GPCR
- 8-K — 2026-09-08
- SCHEDULE 13G/A — 2026-08-06
- 8-K — 2026-08-06
- 10-Q — 2026-08-06
- 8-K — 2026-06-18
- 10-Q — 2026-05-07
- 8-K — 2026-05-07
- 424B5 — 2026-05-07
- 424B5 — 2026-05-07
- ARS — 2026-04-23
Latest GPCR news
- — How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results? (Zacks Investment Research)
- — How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results? (Zacks Investment Research)
- — Novo Down 11% in a Month: How Should Investors Approach the Stock Now? (Zacks Investment Research)
- — Novo Down 11% in a Month: How Should Investors Approach the Stock Now? (zacks.com)
- — LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity? (Zacks Investment Research)
Educational tool only — not investment advice.